AR082844A1 - Derivados de piperidina y su uso para el tratamiento de desordenes metabolicos - Google Patents

Derivados de piperidina y su uso para el tratamiento de desordenes metabolicos

Info

Publication number
AR082844A1
AR082844A1 ARP110102362A ARP110102362A AR082844A1 AR 082844 A1 AR082844 A1 AR 082844A1 AR P110102362 A ARP110102362 A AR P110102362A AR P110102362 A ARP110102362 A AR P110102362A AR 082844 A1 AR082844 A1 AR 082844A1
Authority
AR
Argentina
Prior art keywords
alkyl
carbocyclyl
group
optionally substituted
heterocyclyl
Prior art date
Application number
ARP110102362A
Other languages
English (en)
Inventor
Martin Fleck
Thorsten Lehmann-Lintz
Heike Neubauer
Bernd Nosse
Gerald Juergen Roth
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR082844A1 publication Critical patent/AR082844A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Su uso como medicamentos, métodos para su uso terapéutico y composiciones farmacéuticas que los contienen.Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula general (1) en la que Ar1 se selecciona del grupo Ar1-G1 que consiste en arilo y heteroarilo, todos los cuales pueden estar opcionalmente sustituidos con uno o más sustituyentes RA, en donde dos sustituyentes RA enlazados a átomos de C adyacentes de Ar1 pueden estar conectados uno con otro y juntos forman un grupo de puenteo de alquileno C3-5, en el que 1, 2 ó 3 grupos CH2 pueden estar reemplazados por O, C(=O), S, S(=O), S(=O)2, NH o N(alquilo C1-4)-, en donde el puente de alquileno puede estar opcionalmente sustituido con uno o dos grupos alquilo C1-3; y RA se selecciona del grupo RA-G1 que consiste en H, F, Cl, Br, I, CN, OH, -NO2, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, carbociclilo C3-10, carbociclil C3-10-alquilo C1-3, alquil C1-6-O-, alquenil C3-6-O-, alquinil C3-6-O-, carbociclil C3-10-O-, carbociclil C3-10-alquil C1-3-O-, alquil C1-6-S-, alquil C1-6-S(=O)-, alquil C1-6-S(=O)2-, carbociclil C3-10-S-, carbociclil C3-10-alquil C1-3-S-, alquil C1-4-C(=O)-, carbociclil C3-10-C(=O)-, RN1RN2N-, RN1RN2N-alquil C2-3-O-, RN1RN2N-C(=O)-, RN1RN2N-S(=O)2-, alquil C1-6-C(=O)-NRN1-, alquil C1-6-S(=O)2-NRN1-, alquil C1-6-C(=O)NRN1-alquil C1-3-, HO-C(=O)-, alquil C1-6-O-C(=O)-, heterociclilo, heterociclil-O-, heterociclil-alquilo C1-3, heterociclil-alquil C1-3-O-, heterociclil-C(=O)-, arilo, aril-alquilo C1-3, aril-O-, aril-alquil C1-3-O-, heteroarilo, heteroaril-alquilo C1-3, heteroaril-O-, heteroaril-alquil C1-3-O- y heteroaril-C(=O), en donde en cada uno de carbociclilo y heterociclilo un grupo CH2 puede estar opcionalmente reemplazado por -C(=O)- o -C(=CRAlk2)-, y en donde cada uno de carbociclilo y heterociclilo puede estar opcionalmente sustituido con uno o más alquilo C1-4 que pueden estar opcionalmente sustituidos con uno o más sustituyentes RC, y en donde cada uno de alquilo, carbociclilo y heterociclilo puede estar opcionalmente sustituido con uno o más sustituyentes RC, y en donde cada heterociclilo puede estar opcionalmente sustituido con arilo o heteroarilo, y en donde cada grupo arilo y heteroarilo puede estar opcionalmente sustituido con uno o más sustituyentes L; RC se selecciona del grupo RC-G1 que consiste en F, Cl, Br, CN, OH, alquil C1-4-O-, cicloalquil C3-7-O-, cicloalquil C3-7-alquil C1-3-O-, H2N-, (alquil C1-4)NH-, (alquil C1-4)2N-, H2N-C(=O)-, (alquil C1-4)NH-C(=O)-, (alquil C1-4)2N-C(=O)-, alquil C1-4-C(=O)-, alquil C1-4-S(=O)2-, HO-C(=O)- y alquil C1-4-O-C(=O)-, en donde cada uno de alquilo y cicloalquilo puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados de F y OH; y RN1 se selecciona del grupo RN1-G1 que consiste en H, alquilo C1-6, carbociclilo C3-10, carbociclil C3-10-alquilo C1-3, alquenilo C3-6, alquinilo C3-6, heterociclilo, heterociclil-alquilo C1-3, arilo, aril-alquilo C1-3, heteroarilo y heteroaril-alquilo C1-3, en donde cada uno de carbociclilo y heterociclilo puede estar opcionalmente sustituido con uno o más alquilo C1-4, arilo o aril-alquil C1-3-, y en donde en cada uno de carbociclilo y heterociclilo un grupo CH2 puede estar opcionalmente reemplazado por -C(=O)-, y en donde cada uno de alquilo, carbociclilo y heterociclilo puede estar opcionalmente sustituido con uno o más sustituyentes RC, y en donde cada grupo arilo y heteroarilo puede estar opcionalmente sustituido con uno o más sustituyentes L; RN2 se selecciona entre el grupo RN2-G1 que consiste en H y alquilo C1-6; y RAlk se selecciona entre el grupo RAlk-G1 que consiste en H y alquilo C1-6, que puede estar sustituido con uno o más átomos de F; y Ar2 se selecciona del grupo Ar2-G1 que consiste en fenilo y un sistema de anillos carbocíclico monocíclico aromático de 5 ó 6 miembros, que contiene 1, 2 ó 3 heteroátomos seleccionados de N, O ó S, en donde la totalidad de los grupos antes mencionados puede estar opcionalmente sustituido con uno o más sustituyentes L; y L se selecciona del grupo L-G1 que consiste en F, Cl, Br, CN, OH, alquilo C1-4-, alquil C1-4-O-, alquil C1-4-S-, alquil C1-4-S(=O)2-, alquil C1-4-NRN2-S(=O)2, H2N-, (alquil C1-4)NH-, (alquil C1-4)2N-, H2N-alquil C1-4, (alquil C1-4)NH-alquil C1-4-, (alquil C1-4-)2N-alquil C1-4-, cicloalquil C3-7-, cicloalquil C3-7-alquil C1-3-O- y heterociclilo, en donde cada uno de alquilo puede estar opcionalmente sustituido con uno o más átomos de F y/o con un sustituyente seleccionado de OH, alquil C1-3-O- y CN; y en donde dos sustituyentes L fijados a un grupo arilo o heteroarilo pueden estar enlazados uno con otro y forman un grupo de puenteo de alquileno C2-5, en el que 1 ó 2 grupos -CH2 pueden estar reemplazados por un grupo seleccionado, independientemente uno de otro, de O, S, NH y N(alquilo C1-4)-, en donde el grupo de puenteo de alquileno C2-5 está opcionalmente sustituido con 1 ó 2 grupos alquilo C1-3; X se selecciona del grupo X-G1 que consiste en un grupo alquileno C1-3 de cadena lineal que puede estar sustituido opcionalmente con uno o más alquilo C1-3 y alquil C1-3-O-alquilo C1-3, y en donde dos sustituyentes alquilo pueden estar conectados uno con otro y juntos forman un grupo de puenteo de alquileno C1-5 en el que 1 ó 2 grupos -CH2 pueden estar reemplazados por un grupo seleccionado, independientemente uno de otro, de O, S, NH o N(alquilo C1-4)-, en donde el grupo de puenteo de alquileno C1-5 está opcionalmente sustituido con 1 ó 2 grupos alquilo C1-3; e Y se selecciona del grupo Y-G1 que consiste en -C(=O)-, -C(=S)- y S(=O)2-; RN se selecciona entre el grupo RN-G1 que consiste en H y alquilo C1-3; T se selecciona del grupo T-G1 que consiste en alquilo C1-6, alquenilo C2-6, alquinilo C2-6, carbociclilo C3-10, carbociclil C3-10-alquil C1-3-, alquil C1-6-O-, carbociclil C3-10-O-, carbociclil C3-10-alquil C1-3-O-, alquil C1-6-S-, carbociclil C3-10-S-, carbociclil C3-10-alquil C1-3-S-, alquil C1-4-C(=O)-, alquil C1-4-S(=O)2-, RN1RN2-N, RN1RN2-N-alquil C1-3-, RN1RN2-N-CO, alquil C1-4-C(=O)-RN2N-alquil C1-3-, alquil C1-3-O-N=CH-, alquil C1-4-OC(=O)-RN2N-alquil C1-3-, heterociclilo, arilo, heteroarilo y heteroaril-alquil C1-3-, en donde en cada carbociclilo y heterociclilo un grupo CH2 puede estar opcionalmente reemplazado por -C(=O)-, y en donde cada carbociclilo y heterociclilo puede estar opcionalmente sustituido con uno o más alquilo C1-4 que puede estar opcionalmente sustituido con uno o más sustituyentes RC, y en donde cada uno de alquilo, carbociclilo y heterociclilo puede estar opcionalmente sustituido con uno o más sustituyentes RC, y en donde cada grupo arilo y heteroarilo puede estar opcionalmente sustituido con uno o más sustituyentes L, o los grupos T y RN pueden estar conectados uno con otro y juntos forman un grupo que se selecciona del grupo (T-RN)-G1 que consiste en alquileno C2-5 que puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados de F, Cl, Br, OH, CN, alquilo C1-4, carbociclilo C3-10, carbociclil C3-10-alquilo C1-3, alquil C1-4-O-, cicloalquil C3-7-O-, carbociclil C3-10-alquil C1-3-O-, H2N-, (alquil C1-4)NH-, (alquil C1-4)2N-, alquil C1-4-C(=O)-, alquil C1-4-S(=O)2-, HO-C(=O)-, alquil C1-4-O-C(=O)-, en donde cada uno de alquilo o carbociclilo puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados de RC; incluyendo cualquier tautómero y estereoisómero de los mismos, o una sal de los mismos.
ARP110102362A 2010-07-01 2011-06-30 Derivados de piperidina y su uso para el tratamiento de desordenes metabolicos AR082844A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10168113 2010-07-01

Publications (1)

Publication Number Publication Date
AR082844A1 true AR082844A1 (es) 2013-01-16

Family

ID=44532768

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102362A AR082844A1 (es) 2010-07-01 2011-06-30 Derivados de piperidina y su uso para el tratamiento de desordenes metabolicos

Country Status (16)

Country Link
US (1) US9006450B2 (es)
EP (1) EP2588451B1 (es)
JP (1) JP5654675B2 (es)
KR (1) KR20130113352A (es)
CN (1) CN103080087A (es)
AR (1) AR082844A1 (es)
AU (1) AU2011273455B2 (es)
BR (1) BR112013000059A2 (es)
CA (1) CA2803996A1 (es)
CL (1) CL2012003681A1 (es)
EA (1) EA201201658A1 (es)
IL (1) IL223286A0 (es)
MX (1) MX2013000018A (es)
NZ (1) NZ603724A (es)
TW (1) TW201215390A (es)
WO (1) WO2012001107A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013079668A1 (en) 2011-12-02 2013-06-06 Boehringer Ingelheim International Gmbh Piperidine derivatives, pharmaceutical compositions and uses thereof
US8765959B2 (en) 2011-12-23 2014-07-01 Boehringer Ingelheim International Gmbh Piperidine derivatives
BR112015001908A2 (pt) 2012-07-31 2017-07-04 Syngenta Participations Ag métodos de controle de pragas em soja
US9169205B2 (en) * 2012-10-08 2015-10-27 Boehringer Ingelheim International Gmbh Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
WO2014061693A1 (ja) * 2012-10-17 2014-04-24 塩野義製薬株式会社 新規非芳香族炭素環又は非芳香族複素環誘導体
EP2997024B1 (en) * 2013-05-17 2018-03-28 Boehringer Ingelheim International GmbH Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
EP3043800A1 (en) 2013-09-12 2016-07-20 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
EP3194367B1 (en) 2014-09-17 2021-08-18 Boehringer Ingelheim International GmbH Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes
BR112019005258A2 (pt) * 2016-11-09 2019-06-04 Dow Agrosciences Llc moléculas tendo determinadas utilidades pesticidas, e intermediários, composições, e processos relacionados com as mesmas
WO2019089422A1 (en) * 2017-10-30 2019-05-09 Synblia Therapeutics, Inc. Irak4 inhibitors and uses thereof
US11498904B2 (en) * 2017-11-14 2022-11-15 Merck Sharp & Dohme Llc Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
US11548882B2 (en) 2018-04-27 2023-01-10 Osaka University Benzisoxazole compound
CN109507430B (zh) * 2018-09-06 2022-03-11 重庆医科大学 Sirt7的功能与用途
US11548874B2 (en) * 2020-05-19 2023-01-10 Florida State University Research Foundation, Inc. Antifibrotic compounds and related methods
WO2023132208A1 (ja) * 2022-01-07 2023-07-13 国立大学法人大阪大学 心不全の予防および／または治療用医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0224919D0 (en) 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
GB0303852D0 (en) * 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
BRPI0407676A (pt) 2003-02-19 2006-03-01 Pfizer compostos de triazol,uso e processos para fabricação do mesmo
AU2008225766B2 (en) 2007-03-15 2012-06-07 Novartis Ag Organic compounds and their uses
AU2008339572B2 (en) 2007-12-21 2012-05-10 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
CA2724603A1 (en) 2008-05-28 2009-12-03 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
US8492424B2 (en) 2010-07-01 2013-07-23 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response

Also Published As

Publication number Publication date
EA201201658A1 (ru) 2013-06-28
JP2013533249A (ja) 2013-08-22
JP5654675B2 (ja) 2015-01-14
NZ603724A (en) 2014-06-27
IL223286A0 (en) 2013-02-03
CL2012003681A1 (es) 2013-04-19
WO2012001107A1 (en) 2012-01-05
US20120157425A1 (en) 2012-06-21
EP2588451B1 (en) 2015-12-30
KR20130113352A (ko) 2013-10-15
MX2013000018A (es) 2013-02-01
CN103080087A (zh) 2013-05-01
CA2803996A1 (en) 2012-01-05
AU2011273455A1 (en) 2012-12-13
EP2588451A1 (en) 2013-05-08
BR112013000059A2 (pt) 2015-09-08
US9006450B2 (en) 2015-04-14
AU2011273455B2 (en) 2015-05-14
TW201215390A (en) 2012-04-16

Similar Documents

Publication Publication Date Title
AR082844A1 (es) Derivados de piperidina y su uso para el tratamiento de desordenes metabolicos
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
UA110838C2 (uk) 4-(8-МЕТОКСИ-1-(1-МЕТОКСИПРОПАН-2-ІЛ)-2-(ТЕТРАГІДРО-2H-ПІРАН-4-ІЛ)-1H-ІМІДАЗО[4,5-c]ХІНОЛІН-7-ІЛ)-3,5-ДИМЕТИЛІЗОКСАЗОЛ ТА ЙОГО ЗАСТОСУВАННЯ ЯК ІНГІБІТОРА БРОМОДОМЕНУ
NZ607794A (en) N-acylsulfonamide apoptosis promoters
AR077413A1 (es) Derivados piridin-4-ilo
NI201000022A (es) Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparación, su aplicación como medicamentos, composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
BR112012023382A2 (pt) compostos, composições e métodos de uso de imidazopiridina.
AR083578A1 (es) INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA
AR073138A1 (es) Derivados de dioxa-biciclo (3.2.1) octano- 2,3,4-triol
AR085607A1 (es) Inhibidores de la mst1 quinasa y metodos para su utilizacion
AR060609A1 (es) Compuestos inhibidores de proteinquinasas c-fms.
AR084905A1 (es) Derivados de 2,3-dihidro-furo[2,3-c]piridina, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por la activacion del receptor gpr119 acoplado a proteinas g
NI201800051A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
EA029499B9 (ru) Ингибиторы rorc2 и способы их применения
AR086773A1 (es) Un derivado de cinamida sustituida, el metodo para su preparacion y el uso del mismo
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
CO6460742A2 (es) Derivados de ciclopenta[c]pirrolilalquilcarbamatos de heterociclos de 5 miembros, su preparación y su aplicación en terapéutica
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos

Legal Events

Date Code Title Description
FB Suspension of granting procedure